Onno Akkerman

Zoekresultaten

• 2024

  Evaluation of effectiveness and safety of delamanid-containing regimens using individual patient datasets

  Silva, D. R., Centis, R., D'Ambrosio, L., Visca, D., Tiberi, S., Akkerman, O., Lipman, M. & Migliori, G. B., 1-sep.-2024, In: The International Journal of Tuberculosis and Lung Disease. 28, 9, blz. 470-472 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

• Pancreatitis delays the absorption of first-line anti-TB drugs

  Lever, S., Akkerman, O. W. & Dekkers, B. G. J., 1-mrt.-2024, In: The International Journal of Tuberculosis and Lung Disease. 28, 3, blz. 163-165 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  25 Downloads (Pure)

• Perceptions and clinical practices associated with post-TB health and well-being in the Netherlands

  Spruijt, I., Verhage, A., Procee, F., Vrubleuskaya, N., Mulder, C. & Akkerman, O., okt.-2024, In: IJTLD open. 1, 10, blz. 480-482 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  6 Downloads (Pure)
• 2023

  Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole

  Akkerman-Nijland, A. M., Rottier, B. L., Holstein, J., Winter, R. L. J., Touw, D. J., Akkerman, O. W. & Koppelman, G. H., 26-jun.-2023, In: ERJ Open Research. 9, 3, 4 blz., 00055-2023.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand

  • Drug Therapy 100%
  • Antibiotics 100%
  • Cystic Fibrosis 100%
  • Eradication Therapy 100%
  • Patient with Cystic Fibrosis 100%
  3 Citaten (Scopus)

  68 Downloads (Pure)
• 2022

  Combining digital adherence technology and therapeutic drug monitoring for personalised TB care

  Ghimire, S., Iskandar, D., van der Borg-Boekhout, R., Zenina, M., Bolhuis, M. S., Kerstjens, H. A. M., van Rossum, M., Touw, D. J., Zijp, T. R., van Boven, J. F. M. & Akkerman, O. W., 2022, In: European Respiratory Journal. 60, 4 blz., 2201690.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand

  • Tuberculosis Treatment 100%
  • Therapeutic Drug Monitoring 100%
  • Infection 100%
  • HIV 100%
  • Mixed Infection 100%
  7 Citaten (Scopus)

  179 Downloads (Pure)

• Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

  Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS), Tuberculosis Network European Trials group (TBnet), Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A. L., Goletti, D., Jankovic, M., Kuksa, L., Maurer, F. P., Méchaï, F., Tiberi, S., Van Leth, F., Veziris, N. & Lange, C., 1-mei-2022, In: European Respiratory Journal. 59, 5, 3 blz., 2200388.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  20 Citaten (Scopus)

  43 Downloads (Pure)
• 2021

  TB and COVID-19 co-infection: rationale and aims of a global study

  TB COVID-19 Global Study Grp, Casco, N., Jorge, A. L., Palmero, D., Alffenaar, J.-W., Fox, G., Ezz, W., Cho, J.-G., Skrahina, A., Solodovnikova, V., Bachez, P., Arbex, M. A., Galvao, T., Rabahi, M., Pereira, G. R., Sales, R., Silva, D. R., Saffie, M. M., Miranda, R. C. & Cancino, V. & 31 anderen, Carbonell, M., Cisterna, C., Concha, C., Cruz, A., Salinas, N. E., Revillot, M. E., Farias, J., Fernandez, I., Flores, X., Gallegos, P., Garavagno, A., Guajardo, C., Bahamondes, M. H., Merino, L. M., Munoz, E., Munoz, C., Navarro, I., Navarro, J., Ortega, C., Palma, S., Pardenas, A. M., Pereira, G., Castillo, P. P., Pinto, M., Pizarro, R., Rivas, F., Li, Y., Sharma, S., Akkerman, O. W., Fernandez, S. Q. & Tiberi, S., 1-jan.-2021, In: International Journal of Tuberculosis and Lung Disease. 25, 1, blz. 78-80 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  27 Citaten (Scopus)

  147 Downloads (Pure)
• 2020

  Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin

  van den Elsen, S. H. J., Akkerman, O. W., Jongedijk, E. M., Wessels, M., Ghimire, S., van der Werf, T. S., Touw, D. J., Bolhuis, M. S. & Alffenaar, J.-W. C., 1-mei-2020, In: European Respiratory Journal. 55, 5, 4 blz., 1901903.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  16 Citaten (Scopus)

  176 Downloads (Pure)
• 2019

  Role of Therapeutic Drug Monitoring in Treatment Optimization in Tuberculosis and Diabetes Mellitus Comorbidity

  Dekkers, B. G. J., Akkerman, O. W. & Alffenaar, J. W. C., feb.-2019, In: Antimicrobial Agents and Chemotherapy. 63, 2, 3 blz., ARTN e02074-18.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  14 Citaten (Scopus)

  28 Downloads (Pure)

• Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules

  Bolhuis, M. S., van der Werf, T. S., Kerstjens, H. A. M., de Lange, W. C. M., Alffenaar, J.-W. C. & Akkerman, O. W., 1-dec.-2019, In: European Respiratory Journal. 54, 6, 4 blz., 1900580.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  25 Citaten (Scopus)

  195 Downloads (Pure)
• 2016

  Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients

  Sturkenboom, M. G. G., Akkerman, O. W., van Altena, R., de lange, W. C. M., Kosterink, J. G. W., van der Werf, T. S. & Alffenaar, J.-W. C., 1-okt.-2016, In: European Respiratory Journal. 48, 4, blz. 1237-1239 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  10 Citaten (Scopus)

  37 Downloads (Pure)

• Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV

  Zuur, M. A., Akkerman, O. W., Touw, D. J., van der Werf, T. S., Cobelens, F., Burger, D. M., Grobusch, M. P. & Alffenaar, J.-W. C., sep.-2016, In: European Respiratory Journal. 48, 3, blz. 932-934 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  7 Citaten (Scopus)

  39 Downloads (Pure)

• Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

  Tiberi, S., Sotgiu, G., D'Ambrosio, L., Centis, R., Arbex, M. A., Arrascue, E. A., Alffenaar, J. W., Caminero, J. A., Gaga, M., Gualano, G., Skrahina, A., Solovic, I., Sulis, G., Tadolini, M., Guizado, V. A., De Lorenzo, S., Arias, A. J. R., Scardigli, A., Akkerman, O. W. & Aleksa, A. & 20 anderen, Artsukevich, J., Avchinko, V., Bonini, E. H., Marin, F. A. C., Lopez, L. C., de Vries, G., Dore, S., Kunst, H., Matteelli, A., Moschos, C., Palmieri, F., Papavasileiou, A., Payen, M.-C., Piana, A., Spanevello, A., Vasquez, D. V., Viggiani, P., White, V., Zumla, A. & Migliori, G. B., 1-mei-2016, In: Clinical Infectious Diseases. 62, 9, blz. 1188-1190 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review
  36 Citaten (Scopus)

• End TB with precision treatment!

  van der Burgt, E. P. M., Sturkenboom, M. G. G., Bolhuis, M. S., Akkerman, O. W., Kosterink, J. G. W., de Lange, W. C. M., Cobelens, F. G. J., van der Werf, T. S. & Alffenaar, J.-W. C., feb.-2016, In: European Respiratory Journal. 47, 2, blz. 680-682 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  46 Citaten (Scopus)

  44 Downloads (Pure)

• Implementing tuberculosis entry screening for asylum seekers: the Groningen experience

  Akkerman, O. W., de Lange, W. C. M., Scholvinck, E. H., Wolters, B., Aartsma, Y., van der Werf, T. S. & van Hest, R., jul.-2016, In: European Respiratory Journal. 48, 1, blz. 261-264 5 blz.

  Onderzoeksoutput: Letter › Academic › peer review
  18 Citaten (Scopus)

• Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics

  Ghimire, S., Bolhuis, M. S., Sturkenboom, M. G. G., Akkerman, O. W., de Lange, W. C. M., van der Werf, T. S. & Alffenaar, J.-W. C., jun.-2016, In: European Respiratory Journal. 47, 6, blz. 1867-1869 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  • Disease 100%
  • Adverse Drug Reaction 100%
  • Mycobacterium Tuberculosis 100%
  • Pharmacotherapy 100%
  • Elimination 100%
  62 Citaten (Scopus)

• Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis

  Akkerman, O. W., Odish, O. F. F., Bolhuis, M. S., de lange, W. C. M., Kremer, H. P. H., Luijckx, G.-J. R., van der Werf, T. S. & Alffenaar, J.-W., 15-feb.-2016, In: Clinical Infectious Diseases. 62, 4, blz. 523-524 2 blz.

  Onderzoeksoutput: Letter › Academic › peer review
  56 Citaten (Scopus)

• Reply to Verhaeghe, et al

  Akkerman, O. W., van Hateren, K., Koster, R. A., Luijckx, G.-J. R., van der Werf, T. S. & Alffenaar, J.-W. C., 1-jul.-2016, In: Clinical Infectious Diseases. 63, 1, blz. 146-147 2 blz.

  Onderzoeksoutput: Letter › Academic › peer review

• Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly

  van Altena, R., Akkerman, O. W., Alffenaar, J.-W. C., Kerstjens, H. A. M., Magis-Escurra, C., Boeree, M. J., van Soolingen, D., de Lange, W. C. M., Bolhuis, M. S., Hoefsloot, W., de Vries, G. & van der Werf, T. S., dec.-2016, In: European Respiratory Journal. 48, 6, blz. 1800-1802 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  • Multidrug Resistant Tuberculosis 100%
  • Multi-Drug-Resistant Tuberculosis 100%
  • Shorter Regimen 40%
  • Guideline Development Group 40%
  • Health Care Cost 25%
  51 Citaten (Scopus)

• Statin Adjunctive Therapy for Tuberculosis Treatment

  Alffenaar, J.-W. C., Akkerman, O. W. & van Hest, R., nov.-2016, In: Antimicrobial Agents and Chemotherapy. 60, 11, blz. 7004-7004 1 blz.

  Onderzoeksoutput: Letter › Academic › peer review
  7 Citaten (Scopus)

• Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements

  Sturkenboom, M. G. G., Bolhuis, M. S., Akkerman, O., de Lange, W. C. M., van der Werf, T. S. & Alffenaar, J.-W. C., dec.-2016, In: International Journal of Tuberculosis and Lung Disease. 20, 12, blz. 1695-1696 2 blz.

  Onderzoeksoutput: Letter › Academic › peer review
  4 Citaten (Scopus)
• 2015

  Adequate Design of Pharmacokinetic-Pharmacodynamic Studies Will Help Optimize Tuberculosis Treatment for the Future

  Sturkenboom, M. G. G., Akkerman, O. W., Bolhuis, M. S., de Lange, W. C. M., van der Werf, T. S. & Alffenaar, J.-W. C., apr.-2015, In: Antimicrobial Agents and Chemotherapy. 59, 4, blz. 2474-2474 1 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  8 Citaten (Scopus)

  339 Downloads (Pure)

• Breakpoints and drug exposure are inevitably closely linked

  Alffenaar, J. W. C., Akkerman, O. W., Bolhuis, M. S., Boeree, M. J., de Lange, W. C. M. & van der Werf, T. S., feb.-2015, In: Antimicrobial Agents and Chemotherapy. 59, 2, blz. 1384 1 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  6 Citaten (Scopus)

  245 Downloads (Pure)

• The Never Ending Struggle Against Development of Drug Resistance

  Daskapan, A., Stienstra, Y., Akkerman, O. W., de lange, W. C. M., Kosterink, J. G. W., van der Werf, T. S. & Alffenaar, J.-W. C., 1-jul.-2015, In: Clinical Infectious Diseases. 61, 1, blz. 137-138 2 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  30 Downloads (Pure)

• The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection

  Daskapan, A., de Lange, W. C. M., Akkerman, O. W., Kosterink, J. G. W., van der Werf, T. S., Stienstra, Y. & Alffenaar, J.-W. C., 1-feb.-2015, In: European Respiratory Journal. 45, 2, blz. 569-571 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review

  Open Access

  Bestand
  17 Citaten (Scopus)

  27 Downloads (Pure)
• 2014

  Raltegravir and rifampicin in patients with HIV and tuberculosis

  Klis, S., Daskapan, A., Akkerman, O. W., Alffenaar, J.-W. & Stienstra, Y., nov.-2014, In: Lancet Infectious Diseases. 14, 11, blz. 1046-1047 2 blz.

  Onderzoeksoutput: Letter › Academic › peer review
  1 Citaat (Scopus)

• Strategy To Limit Sampling of Antituberculosis Drugs Instead of Determining Concentrations at Two Hours Postingestion in Relation to Treatment Response

  Akkerman, O. W., van Altena, R., Bolhuis, M. S., van der Werf, T. & Alffenaar, J.-W., jan.-2014, In: Antimicrobial Agents and Chemotherapy. 58, 1, blz. 628 1 blz.

  Onderzoeksoutput: Letter › Academic › peer review
  4 Citaten (Scopus)

  71 Downloads (Pure)
• 2013

  Drug concentration in Lung tissue in multidrug-resistant tuberculosis

  Akkerman, O. W., van Altena, R., Klinkenberg, T., Brouwers, A. H., Bongaerts, A. H. H., van der Werf, T. S. & Alffenaar, J.-W., dec.-2013, In: European Respiratory Journal. 42, 6, blz. 1750-1752 3 blz.

  Onderzoeksoutput: Letter › Academic › peer review
  20 Citaten (Scopus)

• Rifampicin and moxifloxacin for tuberculous meningitis

  Akkerman, O., Pranger, A., van Altena, R., van der Werf, T. & Alffenaar, J.-W., jul.-2013, In: Lancet Infectious Diseases. 13, 7, blz. 568-569 2 blz.

  Onderzoeksoutput: Letter › Academic › peer review
  1 Citaat (Scopus)